[Effect of acid pump antagonist (Revaprazan, Revanex(R)) on result of 13C urea breath test in patients with Helicobacter pylori associated peptic ulcer disease].
OBJECTIVE
Revaprazan (Revanex(R)) is a novel proton pump inhibitor (PPI) that has a somewhat different effect on proton pump compared with the other PPI's, also (called as 'acid pump antagonist'). We aimed to examine the false negative rate of 13C-urea breath test (UBT) in the patients with Helicobacter pylori (H. pylori) associated peptic ulcer disease who were treated with revaprazan and evaluate the anti-urease activity of revaprazan.


METHODS
Total 55 patients were enrolled in this study. They received EGD examination between January 2009 and December 2009 and diagnosed histologically as H. pylori associated peptic ulcer disease. All patients took revaprazan only. Three patients were excluded because of underlying chronic disease and inappropriate breath sampling. The remaining 52 patients had UBT at 0, 2 and 4 weeks of revaprazan use. After 2 weeks of the cessation of revaprazan, they had the fourth UBT.


RESULTS
At 2 and 4 weeks, the false negative rates of UBT were 5.8% and 23.1%, respectively (p=0.05). After 2 weeks of the cessation, the cases of the false negative result were five. Four out of five patients had prolonged negative results on two or three successive tests, and baseline 13C difference value did not predict the false negative results.


CONCLUSIONS
False negative results of UBT were common and increased with prolonged use of acid pump antagonist. As PPI, it had also anti-urease activity and most patients (47/52, 90.4%) reverted to positive results by 2 weeks after the cessation of taking the medication.
Department of Internal Medicine, The Catholic University of Korea School of Medicine, Seoul, Korea.
Ju Hyun
JH
Oak
Woo Chul
WC
Chung
Sung Hoon
SH
Jung
Kang Hyun
KH
Choi
Eun Jung
EJ
Kim
Bong Koo
BK
Kang
Bo Rami
BR
Kang
Si Eun
SE
Kong
Chang Nyol
CN
Paik
Kang Moon
KM
Lee
D001944:Breath Tests; D002247:Carbon Isotopes; D005188:False Negative Reactions; D005260:Female; D016481:Helicobacter Infections / Q000150:complications / Q000175:diagnosis*; D016480:Helicobacter pylori; D006801:Humans; D008297:Male; D008875:Middle Aged; D010437:Peptic Ulcer / Q000188:drug therapy* / Q000382:microbiology; D054328:Proton Pump Inhibitors / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000627:therapeutic use*; D044005:Tetrahydroisoquinolines / Q000627:therapeutic use*; D014508:Urea
D002247:Carbon Isotopes; D054328:Proton Pump Inhibitors; D011744:Pyrimidinones; D044005:Tetrahydroisoquinolines; C108798:YH 1885; D014508:Urea